• Dexcom builds on its history of first-in-market innovations with the launch of its new groundbreaking GenAI platform
  • Dexcom GenAI-enabled technology will leverage Google Cloud’s Vertex AI platform and Gemini models and will initially enhance Stelo’s Weekly Insights feature by providing users with more personalized content based on glucose levels, activity and sleep
  • Proprietary platform lays foundation for future GenAI advancements across the Dexcom product portfolio that will further empower its millions of users to help take control of their health
  • Dexcom to speak on the future of health AI at CES 2025

DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, announced today it has launched a proprietary Generative AI (GenAI) platform, making Dexcom the first CGM manufacturer to integrate GenAI into glucose biosensing technology.1 The new Dexcom GenAI platform will analyze individual health data patterns to reveal a direct association between lifestyle choices and glucose levels while providing actionable insights to help improve metabolic health.

Stelo, the first over-the-counter glucose biosensor cleared2 by the FDA in the United States, is the first Dexcom product to use GenAI-enabled technology to produce weekly insights. The enhancement of Stelo’s Weekly Insights feature started rolling out to users this week. GenAI-powered messaging enhances Stelo’s existing Weekly Insights by offering users more personalized tips, recommendations, and education related to diet, exercise, and sleep that are contextualized within the Stelo app.

“The launch of our GenAI platform reinforces our long-standing reputation as the glucose biosensing leader and opens the door for future advancements across our product portfolio,” said Jake Leach, executive vice president and chief operating officer at Dexcom. “Innovation is at the core of what we do. We look forward to introducing additional GenAI-powered features over the next year to help users contextualize their health information and make proactive, informed lifestyle decisions.”

Dexcom leveraged Google Cloud’s cutting-edge Vertex AI platform and Gemini models as the foundation to build its proprietary GenAI platform.

“By bringing the power of Google Cloud’s Vertex AI and Gemini to Dexcom’s innovative glucose biosensing technology, users will have more personalized insights to help them make the best decisions for their health,” said Chris Sakalosky, vice president of Strategic Industries for Google Cloud. “Dexcom is empowering people to take control of their metabolic health like never before, and it’s just the beginning of what’s possible as leading organizations bring GenAI to healthcare.”

Leach will join other industry leaders on a panel at CES 2025 to speak to Health AI in 2030. The panel of experts will discuss how AI will revolutionize health care over the next five years and will be held on Jan. 8, 2025, at 2 p.m. PT at the Venetian on level 4 in Marcello 4404. Learn more about the panel here.

About Dexcom

Dexcom empowers people to take control of health through innovative biosensing technology. Founded in 1999, Dexcom has pioneered and set the standard in glucose biosensing for more than 25 years. Its technology has transformed how people manage diabetes and track their glucose, helping them feel more in control and live more confidently.

Dexcom. Discover what you’re made of. For more information, visit www.dexcom.com.

1 Dexcom, Data on file, 2024. 2 Dexcom, Stelo User Guide, 2024.

STELO IMPORTANT INFORMATION: Consult your healthcare provider before making any medication adjustments based on your sensor readings and do not take any other medical action based on your sensor readings without consulting your healthcare provider. Do not use if you have problematic hypoglycemia. Failure to use Stelo and its components according to the instructions for use provided and to properly consider all indications, contraindications, warnings, and cautions in those instructions for use may result in you missing a severe hypoglycemia (low blood glucose) or hyperglycemia (high blood glucose) occurrence. If your sensor readings are not consistent with your symptoms, a blood glucose meter may be an option as needed and consult your healthcare provider. Seek medical advice and attention when appropriate, including before making any medication adjustments and/or for any medical emergency.

INDICATIONS FOR USE: The Stelo Glucose Biosensor System is an over-the-counter (OTC) integrated Continuous Glucose Monitor (iCGM) intended to continuously measure, record, analyze, and display glucose values in people 18 years and older not on insulin. The Stelo Glucose Biosensor System helps to detect normal (euglycemic) and low or high (dysglycemic) glucose levels. The Stelo Glucose Biosensor System may also help the user better understand how lifestyle and behavior modification, including diet and exercise, impact glucose excursion. The user is not intended to take medical action based on the device output without consultation with a qualified healthcare professional.

Dexcom, Dexcom Clarity, Dexcom Follow, Dexcom One, Dexcom Share, Stelo, and any related logos and design marks are either registered trademarks or trademarks of Dexcom, Inc. in the United States and/or other countries. ©2024 Dexcom, Inc. All rights reserved.

Category: IR

Media Contact Janika Kelly mediarelations@dexcom.com Investor Contact Sean Christensen investor-relations@dexcom.com

DexCom (NASDAQ:DXCM)
Historical Stock Chart
From Nov 2024 to Dec 2024 Click Here for more DexCom Charts.
DexCom (NASDAQ:DXCM)
Historical Stock Chart
From Dec 2023 to Dec 2024 Click Here for more DexCom Charts.